First time identification of Pandoraea sputorum from a patient with cystic fibrosis in Argentina: a case report by Martina, Pablo F. et al.
CASE REPORT Open Access
First time identification of Pandoraea
sputorum from a patient with cystic fibrosis
in Argentina: a case report
Pablo F. Martina1,5,6, Mónica Martínez2, Guillermo Frada2, Florencia Alvarez3, Lorena Leguizamón2, Claudia Prieto5,
Carolina Barrias2, Marisa Bettiol4, Antonio Lagares3, Alejandra Bosch5, Julián Ferreras1,6* and Martha Von Specht2,6*
Abstract
Background: Pandoraea species are considered emerging pathogens in the context of cystic fibrosis (CF) and
are difficult to identify by conventional biochemical methods. These multidrug resistant bacteria remain poorly
understood particularly in terms of natural resistance, mechanisms of acquired resistance and impact on the
prognosis of the disease and the lung function. Among them, Pandoraea sputorum has been previously described
in few cases of CF patients from Spain, Australia, France and United States, underlining the need of more clinical
data for a better knowledge of its pathogenicity. This is the first report relating to P. sputorum in a CF patient in
Argentina.
Case presentation: Pandoraea sputorum was identified in a nine-year-old cystic fibrosis patient from Argentina,
after treatment failure during an exacerbation. The isolates were successfully identified by combining molecular
techniques based on 16S rRNA sequencing and mass spectrometry (MS) methods, after reassessing previous
misidentified isolates by conventional methods. After first isolation of P. sputorum, patient’s clinical condition
worsened but later improved after a change in the treatment. Although isolates showed susceptibility to
trimethoprim–sulfamethoxazole and imipenem, in our case, the antibiotic treatment failed in the eradication
of P. sputorum.
Conclusions: All combined data showed a chronic colonization with P. sputorum associated to a deterioration
of lung function. We noted that the presence of P. sputorum can be underestimated in CF patients and MALDI-TOF MS
appears to be a promising means of accurate identification of Pandoraea species.
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Background
In cystic fibrosis (CF) patients, the main cause of mor-
bidity and mortality is the decline in the pulmonary
function subsequent to pathogenic colonization with
non-fermenting Gram negative bacteria (NFGNB) [1].
Nevertheless, diverse bacterial species exhibit distinct
degrees of pathogenicity and sensitivity patterns, requir-
ing different clinical managements [2]. Regularly, a series
of opportunistic pathogens colonizes the CF lung
throughout life, often culminating in chronic infection
with Pseudomonas aeruginosa and, less frequently, with
Burkholderia cepacia complex (Bcc) organisms. Other
opportunistic Gram-negative bacteria are also encoun-
tered. They include various Enterobacteriaceae, Steno-
trophomonas maltophilia, Achromobacter xylosoxidans
[1, 3] and species that are only occasionally associated
with human infections apart from CF, such as Cupria-
vidus, Ralstonia, and Pandoraea species. Some of
these species have been associated with poor out-
comes in CF, and the role that others may play in
disease progression remains uncertain [2]. Bacteria
from the Pandoraea genus (P. pulmonicula, P. pnome-
nusa, P. apista, P. norimbergensis and P. sputorum)
are NFGNB that are being considered as emerging
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multi-drug resistant pathogens in the context of CF
[4, 5]. As they are still poorly known, particularly in
terms of mechanisms of natural or acquired resistance
and of their impact on lung function and the progno-
sis of the disease [5], more information is needed it
to evaluate their pathogenic role. Conventional micro-
biology methods remain problematic for the accurate
identification of Pandorea species and misidentifica-
tion with bacteria of the genus Burkholderia or
Ralstonia has been reported [6–8]. Moreover, isolates
from CF patients with persistent pathogenic
colonization often lose their characteristic phenotypes
or growth conditions [9]. Therefore, descriptions of
infections due to Pandoraea species in CF patients
could be underestimated. The availability of MALDI-
TOF MS in clinical microbiology diagnosis allows a
quick and better identification of bacterial species,
especially Pandoraea species [5, 8, 10–12]. In this
study we report for the first time in Argentina, a lung
colonization with Pandoraea sputorum, in a young CF
patient who did not respond to antibacterial empirical
treatment. Identification was possible after reassessing
historical identification results obtained by conven-
tional methods, using MALDI-TOF MS and sequen-
cing of 16S rRNA gene.
Case presentation
A 9-year-old boy who was diagnosed with CF at
29 months (heterozygous genotype F508del; sweat test
positive: Na 74 mEq/l and Cl de 63 mEq/l.), was trans-
ferred to our CF unit with a 5 years history of chronic
bronchopulmonary colonization with Pseudomonas aer-
uginosa and Staphylococcus aureus. When the first
microbiological cultures (always sputum samples) were
performed in our laboratory in July 2014, P. sputorum
was detected together with S. aureus, but was initially
reported as S. maltophilia (Fig. 1). Previously, his
pulmonary function test revealed a forced expiratory
volume in 1 s (FEV1) of 83%, and the preceding respira-
tory exacerbations were treated empirically with ceftazi-
dime, amikacin and with aerosolized tobramycin. From
the time of the first isolation of P. sputorum and during
the next 2 months, his clinical condition worsened and
exacerbations with increased cough and secretions were
observed. The patient was treated with trimethoprim-
sulfamethoxazole (4/20 mg/kg/day) plus ciprofloxacin
(15 mg/kg/day) and with aerosolized colistin (2 million
units twice daily), however, his lung function declined
(FEV1 45%). In June 2015, the patient showed exacerba-
tions with a dramatic deterioration of his pulmonary
function (FEV1 27%). A combined therapy for three-
weeks of imipenem (80 mg/kg/day), amikacin (40 mg/
kg/day), and inhaled colistin was initiated. Consequently,
his clinical condition improved with a significant reduc-
tion in sputum volume and cough (FEV1 40%). Five
months later, his clinical condition was stable. In April
2016, a new respiratory sample was positive for P. spu-
torum, confirmed by MALDI-TOF MS, together with
with S. aureus and P. aeruginosa.
Our laboratory records indicated that sputum cultures
during patient’s exacerbations and/or routine follow-up
visits until July 2015, showed colonies of NFGNB with-
out any clear phenotypic differences and S. aureus.
Conventional identification of purple colonies recovered
on B. cepacia complex selective agar plates (BCSA;
Britania S.A, Argentina) was performed to some NFGNB
Fig. 1 Time course outlines antibiotics treatment, lung function and culture results
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colonies. We used a combination of phenotypic tests
[13] like oxidase activity, DNase, carbohydrate
oxidation-fermentation, lysine and arginine decarboxyl-
ase, and motility tests. After these tests, isolates were
reported as NFGNB (n = 2), S. maltophilia (n = 2), B.
cepacia complex (n = 1) and S. aureus (n = 7). Later, one
of the Gram-negative isolates was identified as Borde-
tella hinzii with a high identification confidence level
(99% probability) using VITEK2 automatic system (bio-
Mérieux, France). Due to the inaccuracy of biochemical
tests, we decided to reassess the identification of all
NFGNB isolates (n = 5) by Matrix Assisted Laser Des-
roption Ionisation-Time of flight (MALDI-TOF) mass
spectrometry (MS), using an Ultraflex MALDI TOF/
TOF instrument and the MALDI Biotyper 3.1 software
(Bruker Daltonics, Bremen, Germany). The five isolates
were identified as Pandorea sputorum at species-level
(score >2). Hierarchical cluster analysis based on
MALDI-TOF MS spectra comparison clustered together,
clinical isolates and the reference strain P. sputorum
DSM 21091T, while P. apista, P. pnomenusa, P. pulmoni-
cola and P. norimbergensis were in a separate branch
(Fig. 2). In addition, genetic relatedness was determined
by fingerprinting analysis like BOX-PCR (Interspersed
repetitive element) and ERIC-PCR (enterobacterial
repetitive intergenic consensus) [14], revealing indistin-
guishable patterns among all our clinical isolates (data
not shown). Finally, a subsequent full characterization
through PCR and sequencing of 16S rRNA gene was
performed using the corresponding universal primers
(27 F and 1492R), previously published [15]. Sequence
analysis of a 1400-bp fragment of the 16S rRNA gene of
one of patient’s isolate (P. sputorum HP020) was per-
formed. The corresponding sequence (GenBank acces-
sion KX258224) showed 99% of similarity with P.
sputorum DSM21091T (GenBank accession CP010431),
which confirmed the results obtained by MALDI-TOF
MS analysis. The phylogenetic relationship among
them was investigated by using MEGA 6.0 software
(http://www.megasoftware.net) (Fig. 3).
Antibiotic susceptibility testing was performed using a
disk diffusion method according to the recommenda-
tions of the committee of CLSI [16]. Susceptibility pat-
terns were also identical for all isolates. In the absence
of interpretive susceptibility criteria for strains of
Pandoraea, results were interpreted using CLSI criteria
for “other non-Enterobacteriaceae” isolates. The micro-
organism was resistant to amikacin, ceftazidime, cefe-
pime, meropenem, gentamicin, aztreonam and colistin
and susceptible to imipenem and trimethoprim-
sulfamethoxazole. Minimum inhibitory concentrations
(MIC, mg/L) were estimated by Vitek2 Compac® for
amikacin (≥64), ceftazidime (≥64), cefepime (≥64), cipro-
floxacine (≥4), colistin (≥16), meropenem (≥16), genta-
micin (≥64), piperacillin-tazobactam (≥128), imipenem
(≤0,25) and trimethoprim-sulfamethoxazole (TMS, ≤ 1/
20), which confirms the susceptibility profile.
Discussion and Conclusions
In the last decade, many emerging multidrug resistant
pathogens have been described in CF patients including
new species of the Burkholderia cepacia complex,
Fig. 2 Cluster analysis of MALDI-TOF MS spectra of Pandoraea sputorum isolates and 14 reference strains of related species (MALDI Biotyper 3.1
database). A standard MainSpectrum was created to clinical isolate P. sputorum HP020. Isolates from the same patient are represented in MSPs
strains 0020, 0021, 0027, 0028 and 0029. Distance is displayed in relative units
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Brevundimonas diminuta, Inquilinus limosus, Acetobac-
ter indonesiensis, Achromobacter xylosoxidans, Ochro-
bactrum anthropi, and bacteria of the genus Pandoraea
[17, 18]. The pathogenicity of Pandoraea species re-
mains controversial. These bacteria have been occasion-
ally recovered from the lung transplant and/or
respiratory tract of CF patients, as well as from blood
cultures in non-CF patients and environmental samples
[2, 4, 8, 19]. In our review of the bibliography, we found
few cases of CF patients chronically colonized with P.
sputorum: one case from Australia [8], two cases from
Spain [10, 11], and one case from France [5]. Interest-
ingly, in our CF patient, S. aureus and P. aeruginosa
were eventually isolated from respiratory tract cultures
together with P. sputorum. This situation makes more
difficult to know the real contribution of P. sputorum to
the clinical condition of our patient. In this regard, inter-
mittent or persistent colonization with Pandoraea spe-
cies, that sometimes coincides with a deterioration in
lung function, has been reported in addition to clinical
evidence of invasive potential [8, 10, 11, 18]. Further-
more, besides the inability of Pandoraea species to pro-
duce a biofilm in the respiratory tract [20], it remains
still unclear the role of different virulence factors, mech-
anisms of pathogenicity, the possibility of transmission
between patients, and their role in lung damage in CF
patients. This situation emphasizes the importance of
having more data about clinical cases. The Pandoraea
genus is multidrug resistant and treatment may be prob-
lematic. In our case, P. sputorum was only susceptible to
imipenem and TMS, with a low MIC for imipenem
(≤0,25 mg/L), and although the treatment failed to eradi-
cate the bacteria, the clinical condition improved. This
pattern of being resistant to carbapenem and merope-
nem but sensitive to imipenem, appears to be unique to
most Pandoraea genus [5, 21], and it can be a practical
guideline in the earliest identification steps.
It is documented, when applying only conventional iden-
tification phenotypic methods, the microbiology laboratory
commonly misidentifies this pathogen as Ralstonia, Steno-
trophomonas or Burkholderia species [6–8]. It has been
also noted the limitations of the sequences of 16S rRNA
and gyrB genes for differentiating the Pandoraea species
[8, 22]. The accuracy and usefulness of MALDI-TOF as a
routine technique for rapid identification of bacterium was
demostrated. Nevertheless, one factor limiting the use of
MALDITOF MS is the scant reference data sets for micro-
organisms that are infrequently isolated from clinical speci-
mens [10]. Due to these limitations, a polyphasic approach
for an accurate identification is recommended. In our CF
patient, all isolates were identified as P. sputorum, combin-
ing 16S rRNA PCR and sequencing, and a MALDI-TOF
MS proteomic platform. Lastly, to determine persistence
over time of the same P. sputorum isolate, as generally oc-
curs with P. aeruginosa and Bcc in CF patients, a molecu-
lar epidemiological analysis was performed [2, 23]. BOX-
PCR and ERIC-PCR showed indistinguishable patterns
among all isolates of P. sputorum (includeding last isolate
collected in April 2016), indicating a possible chronic
colonization, which is defined here as three positive cul-
tures of the same strain isolated within a 6-month period.
In conclusion, we noted that the presence of P. spu-
torum can be underestimated in CF patients when using
conventional biochemical identification methods. We
also showed that P. sputorum may have a potential role
in pulmonary function deterioration when chronically
Fig. 3 Phylogenetic tree based on the 16S rDNA sequence of Pandoraea sputorum HP020 (KX258224) strain. The tree was constructed using a
neighbor-joining method, and 1000 bootstrap by using MEGA6 software as previously described [22]. Values above the lines are bootstrap values
expressed as percentages
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colonized CF patients, emphasizing the need to imple-
ment control policies to protect CF community. This is
particularly relevant, as in our case, the treatment failed
despite sensitivity to imipenem and trimethoprim–sulfa-
methoxazole. Finally, MALDI-TOF MS appears to be an
excellent tool for an accurate identification of organisms
of this genus.
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